Biocon Biologics secures US market entry date for Bmab 1200

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA

Lupin receives tentative USFDA approval for Rivaroxaban Tablets USP

Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24

The company has received five final approvals

Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin Tablets

This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa

Aurobindo Pharma receives USFDA approval for Darunavir Tablets

Lupin receives tentative approval from USFDA for Canagliflozin Tablets

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor

Sanofi completes closing for potential first-in-class vaccine against ExPEC

Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis

Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets

This product will be manufactured at Lupin’s Pithampur facility in India

Lupin enters into BTA with Lupin Manufacturing Solutions

Lupin enters into BTA with Lupin Manufacturing Solutions

NATCO files generic Erdafitinib Tablets in USA

Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma